Ratings Evogene Ltd. Nasdaq

Equities

EVGN

IL0011050551

Market Closed - Nasdaq Other stock markets 21:30:01 31/05/2024 BST			5-day change	1st Jan Change
0.745 ^USD	-2.75%		-9.14%	-11.31%

05-23	Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M	MT
05-23	Evogene Ltd. Provides Revenue Guidance for the Year 2024	CI

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
EVOGENE LTD.	-11.31%	37.66M	-	-
MODERNA, INC.	+43.36%	54.64B		B-
IQVIA HOLDINGS INC.	-5.31%	39.92B		B
LONZA GROUP AG	+37.52%	38.82B		A
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B		B-
CELLTRION, INC.	-12.56%	26.22B		C
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B		B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B		B+
BIO-TECHNE CORPORATION	+0.04%	12.16B		B+
MEDPACE HOLDINGS, INC.	+26.04%	11.94B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes